Report ID: SQMIG35B2205
Companion Diagnostics for Oncology Market Size, Share, Growth Analysis, By Component(Products, and Services), By End User(Hospitals, Pathology/Diagnostic Laboratories, and Academic Medical Centers), By Indication(Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia), By Technology(Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35B2205 |
Region:
Global |
Published Date: May, 2024
Pages:
215
|
Tables:
122 |
Figures:
76
Companion Diagnostics for Oncology Market Competitive Landscape
Companion diagnostics for oncology market players should solely focus on R&D to foster innovation and stand out from the competition. The requirement of huge amount of capital to enter this market makes it a difficult one for start-ups and new companies looking to innovate. Companion diagnostics for oncology providers can also emphasize improving the reimbursement scenario for companion diagnostics to maximize their revenue generation potential in the long run.
Top Player’s Company Profiles
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- ARUP Laboratories
- Biocartis
- Exact Sciences
- Myriad Genetics Inc.
- Sysmex Corporation
- Abbott
- Genedrive
- Genomic Health
- Archer Dx
- Agilent Technologies Inc.
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Invivoscribe Inc.
- Guardant Health
- Foundation Medicine
- Illumina Inc.
- Amoy Dx
Companion Diagnostics for Oncology Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
